Viatris (VTRS)
(Real Time Quote from BATS)
$11.02 USD
+0.13 (1.19%)
Updated Jul 11, 2024 11:24 AM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VTRS 11.02 +0.13(1.19%)
Will VTRS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VTRS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VTRS
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
Here's Why You May Invest in Theravance (TBPH) Stock Now
VTRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down
Viatris (VTRS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Other News for VTRS
Viatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture
U.S. Department of Justice Informs Viatris That It No Longer Considers Mylan a Subject of Generic Drug Industry Antitrust Investigation
S&P 500 Four Under Five
Viatris Named to TIME's World's Most Sustainable Companies 2024 List
Goldman’s top 50 high Sharpe Ratio stocks